WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H591372
CAS#: 1506-17-8
Description: Indanamin is a biochemical.
Hodoodo Cat#: H591372
Name: Indanamin
CAS#: 1506-17-8
Chemical Formula: C13H16ClN
Exact Mass: 221.97
Molecular Weight: 221.730
Elemental Analysis: C, 70.42; H, 7.27; Cl, 15.99; N, 6.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Indanamin; AGN 1133; AGN-1133; AGN1133
IUPAC/Chemical Name: 1-Indanamine, N-methyl-N-2-propynyl-, hydrochloride
InChi Key: DWMQCWYIMZWFPL-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H15N.ClH/c1-3-10-14(2)13-9-8-11-6-4-5-7-12(11)13;/h1,4-7,13H,8-10H2,2H3;1H
SMILES Code: C#CCN(C)C1CCC2=C1C=CC=C2.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 221.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pati ML, Abate C, Contino M, Ferorelli S, Luisi R, Carroccia L, Niso M, Berardi F. Deconstruction of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety to separate P-glycoprotein (P-gp) activity from σ2 receptor affinity in mixed P-gp/σ2 receptor agents. Eur J Med Chem. 2015 Jan 7;89:691-700. doi: 10.1016/j.ejmech.2014.11.001. Epub 2014 Nov 4. PubMed PMID: 25462276.
2: Silva LF Jr, Siqueira FA, Pedrozo EC, Vieira FY, Doriguetto AC. Iodine(III)-promoted ring contraction of 1,2-dihydronaphthalenes: a diastereoselective total synthesis of (+/-)-indatraline. Org Lett. 2007 Apr 12;9(8):1433-6. Epub 2007 Mar 20. PubMed PMID: 17371034.
3: Gardner EL, Liu X, Paredes W, Giordano A, Spector J, Lepore M, Wu KM, Froimowitz M. A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction. Neuropharmacology. 2006 Oct;51(5):993-1003. Epub 2006 Aug 8. PubMed PMID: 16901516.
4: McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Votaw JR, Nemeroff CB, Goodman MM. Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents. Nucl Med Biol. 2005 Aug;32(6):593-605. PubMed PMID: 16026706.
5: Chazalette C, Masereel B, Rolin S, Thiry A, Scozzafava A, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. PubMed PMID: 15501040.
6: Yu H, Kim IJ, Folk JE, Tian X, Rothman RB, Baumann MH, Dersch CM, Flippen-Anderson JL, Parrish D, Jacobson AE, Rice KC. Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. PubMed PMID: 15115403.
7: Froimowitz M, Wu KM, Moussa A, Haidar RM, Jurayj J, George C, Gardner EL. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem. 2000 Dec 28;43(26):4981-92. PubMed PMID: 11150168.
8: Suehiro M, Scheffel UA, Ravert HT, Ricaurte GA, Hatzidimitriou G, Dannals RF, Bøgesø KP, Wagner HN Jr. Highly potent indanamine serotonin uptake blockers as radiotracers for imaging serotonin uptake sites. Nucl Med Biol. 1994 Nov;21(8):1083-91. PubMed PMID: 9234366.
9: Suehiro M, Scheffel U, Dannals RF, Wilson AA, Ravert HT, Wagner HN Jr. Synthesis and biodistribution of a new radiotracer for in vivo labeling of serotonin uptake sites by PET, cis-N,N-[11C]dimethyl-3-(2',4'-dichlorophenyl)-indanamine (cis-[11C]DDPI). Int J Rad Appl Instrum B. 1992 Jul;19(5):549-53. PubMed PMID: 1399685.
10: Rosenzweig-Lipson S, Bergman J, Spealman RD, Madras BK. Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites. Psychopharmacology (Berl). 1992;107(2-3):186-94. PubMed PMID: 1377395.
11: Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther. 1989 Oct;251(1):131-41. PubMed PMID: 2529364.
12: Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985 Oct 22;116(3):313-7. PubMed PMID: 3935467.
13: Hyttel J, Larsen JJ. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem. 1985 May;44(5):1615-22. PubMed PMID: 2580950.
14: Arnt J, Christensen AV, Hyttel J. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1985 Apr;329(2):101-7. PubMed PMID: 2409454.
15: Weppner HG, Merle H, Schlepper M. [Changes in hemodynamics and contractility during supraventricular tachycardias and after electrical or aprindin-induced termination (author's transl)]. Arzneimittelforschung. 1976;26(12):2205-8. German. PubMed PMID: 1037277.
16: Kroll DA, Lucchesi BR. Antiarrhythmic and antifibrillatory properties of aprindine. J Pharmacol Exp Ther. 1975 Aug;194(2):427-34. PubMed PMID: 1151768.
17: Kametani T, Kigasawa K, Hiiragi M, Ishimaru H, Saito S. [Syntheses of analgesics. XXIX. Synthesis and pharmacological activity of N-(2-aminoethyl)-2-indanamine derivatives]. Yakugaku Zasshi. 1972 Apr;92(4):431-6. Japanese. PubMed PMID: 5065439.
18: Irino O, Tateishi M, Miura C, Fukawa K. Studies on absorption, biotransformation and excretion of drug. II. Metabolism of 2-indanamine. Chem Pharm Bull (Tokyo). 1972 Apr;20(4):734-40. PubMed PMID: 5057393.
19: Cannon JG, Kim JC, Aleem MA. Centrally acting emetics. 6. Derivatives of -naphthylamine and 2-indanamine. J Med Chem. 1972 Apr;15(4):348-50. PubMed PMID: 5019548.
20: Huebner CF, Donoghue EM, Plummer AJ, Furness PA. N-methyl-n-2-propynyl-l-indanamine. A protent monoamine oxidase inhibitor. J Med Chem. 1966 Nov;9(6):830-2. PubMed PMID: 5972038.
